Fulgent Genetics (FLGT) Net Income towards Common Stockholders (2015 - 2026)

Fulgent Genetics has disclosed Net Income towards Common Stockholders across 11 years of filings, most recently posting -$24.8 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$24.8 million, down 115.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$73.8 million (down 81.01% YoY), and the FY2025 annual result was -$60.5 million, down 41.69% from the prior year.
• Net Income towards Common Stockholders came in at -$24.8 million for Q1 2026 at Fulgent Genetics, down from -$23.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $153.6 million in Q1 2022 to a low of -$128.1 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is -$13.1 million (2023), against an average of -$9.1 million.
• Across the five-year window, Net Income towards Common Stockholders plunged 1075.95% in 2023 and jumped 95.41% in 2024, its largest moves.
• Fulgent Genetics' Net Income towards Common Stockholders stood at -$24.1 million in 2022, then tumbled by 432.27% to -$128.1 million in 2023, then surged by 95.41% to -$5.9 million in 2024, then sank by 297.72% to -$23.4 million in 2025, then retreated by 6.01% to -$24.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$24.8 million (Q1 2026), -$23.4 million (Q4 2025), and -$6.6 million (Q3 2025), per Business Quant data.